FAQ'S

---

What exchange is Bradmer Pharmaceuticals traded on, and what is the symbol?
As of April 18, 2006, Bradmer Pharmaceuticals is traded on the Toronto Stock Exchange under the symbol "BMR".  Prior to this date, the Company was traded on the TSX Venture Exchange.  

Who is the proper Investor Relations contact person?
Ross Marshall
Equicom Group Inc.
416-815-0700 x238
rmarshall@equicomgroup.com
 

Who is Bradmer Pharmaceuticals’ Registar and Transfer Agent?
Communication concerning transfer requirements, lost certificates, change of name or address and other similar inquiries should be addressed to our transfer agent:
 
Equity Transfer & Trust Company
200 University Avenue, Suite 400
Toronto, ON  M5H 4H1
Tel: (416) 361-0152
Fax: (416) 361-0470
E-Mail: info@equitytransfer.com
Website:  www.equitytransfer.com
Frequently Asked Shareholder Questions:  http://www.equitytransfer.com/ShareholderFAQ.aspx

Which equity analysts publish research on Bradmer Pharmaceuticals?

Versant Partners
Douglas W. Loe, PhD, MBA

Macquarie Capital Markets
Stefan Quenneville, CFA

RBC Capital Markets
Philippa Flint
  

When are Bradmer Pharmaceuticals’ fiscal quarter and year-end dates?
Bradmer Pharmaceuticals has elected to operate on a fiscal year ending December 31.  Our quarterly reporting periods are March 31, June 30, September 30 and December 31. 
 
How can I get a copy of Bradmer Pharmaceuticals’s most recent annual report?
All financial filings, when published, will be made available for viewing or download in the Financials portion of our website.   If you require a hard copy, please fill out the Info Request Form.

When did Bradmer Pharmaceuticals commence operations?
Bradmer Pharmaceuticals Inc. was incorporated on June 16, 2005 pursuant to the provisions of the Business Corporations Act (Ontario).  On September 22, 2005, the Company issued shares pursuant to an initial public offering on the TSX Venture Exchange. The Company went public as a Capital Pool Company, as that term is defined in TSX Venture Exchange Policy 2.4 (the “CPC Policy”).    During 2005, the Company did not carry on any business operations other than the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction, as that term is defined in the CPC Policy.  On February 8, 2006, the Company obtained shareholder approval for an amalgamation with Blue Devil Pharmaceuticals Inc., and on February 10, 2006, the Company completed this amalgamation.  Shortly thereafter, the Qualifying Transaction received the final approval of the TSX Venture Exchange and the Company commenced full operations.